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National Danish Ethical CommitteeRecent years have seen an increase in screening for
asymptomatic peripheral arterial disease (PAD)
among patients hospitalised for stroke and cardiac
disease. Such screening is being performed without
information or patient consent, with minimal conse-
quences in case of a positive finding, and without
evidence of its cost effectiveness.1 A similar is appar-
ently being reported in this edition of the EJVES,
where A˚lund et al. report findings of screening-
diagnosed abdominal aortic aneurysms (AAA)
among patients referred to vascular examination due
to PAD. Among 9,296 referred patients, 5,924 were
screened which makes the study the second largest
selective screening study for AAA ever reported. A
total of 179 subjects were found to have an AAA.
In men aged 60 years or more, the AAA prevalence
was 4.0% in the absence and 7.3% (5.7e8.9%) in the
presence of an arterial stenosis. Women aged 65 or
more with a diagnosed stenosis had a PAD preva-
lence of 3%. In all, 64% were screened, but the
screening proportion rose to 82% at the end of the
period. Such selective screening would therefore, in-
deed, seem to be feasible, and the most important
question is therefore whether it is acceptable. The au-
thors write that screening for AAA was introduced
as a clinical routine at the vascular laboratory and
that they included the infrarenal aortic diameter on
all Duplex protocols. No exclusion criterion was
used and the patients were not explicitly informedDOI of original article: 10.1016/j.ejvs.2007.12.014.
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who informed the patient of the result, handled
the information. This practice has some debatable
aspects.
Firstly, the participants seem not to have been
informed routinely, or even to have accepted the
screening offer before commencement of the screen-
ing. Individual acceptance of a screening offer should
be obtained after a proper information procedure that
includes the mentioning of the potential consequences
of (non-)acceptance, allows time for reflection, and
underscores the patient’s independence and sover-
eignty. Secondly, if the participants had, indeed,
been informed, the screening procedure ought to
have been organised under more independent condi-
tions and after the vascular consultation. Performing
the screening before the consultation introduces the
risk that patients dare not turn down the offer for
fear of the potential consequences of declining the
invitation. Thirdly, a number of conditions must be
fulfilled before screening for an asymptomatic condi-
tion can be advocated.
These conditions were initially formulated by the
WHO and were later expanded by the Council of
Europe.2,3 For instance, an acceptable treatment
must be available. However, no exclusion criteria
were formulated, so patients with high co-morbidity
were included, which leaves a risk of diagnosing
a high proportion of patients with AAAs who cannot
be offered surgery, and who, if treated, would have an
unacceptably high mortality and morbidity. In addi-
tion, the participants who are saved will have a shorter
survival than the background population and they
will be facing an increased morbidity due to otherr Surgery. Published by Elsevier Ltd. All rights reserved.
676 J. S. Lindholt and U. Fastingcardiovascular events. Furthermore, the group with
the highest prevalence would already be covered by
the recommended population screening of men aged
65, and the AAAs found among the younger men
may not constitute a problem before they reach the
age of 65, and they would then be diagnosed by
a mass screening programme. Taken together, these
reservations sum up to the conclusion that such
screening programmes may be cost-ineffective. We
therefore strongly agree with the authors that studies
evaluating the benefit and costs of such selective high-
risk screening are, indeed, warranted.Eur J Vasc Endovasc Surg Vol 35, June 2008References
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